Evidence map›Paper›PMID 40084096›Full record

ArticleMediterranean journal of hematology and infectious diseases2025

Leukemia Cutis in a Patient with Acute Myeloid Leukemia Undergoing Azacitidine-Venetoclax: Case Presentation and Review of the Literature.

Elisa Buzzatti, Cristina Mauro, Caterina Botti, Roberta Presicci, Giovangiacinto Paterno, Raffaele Palmieri, Carmelo Gurnari, Flavia Mallegni, Elisa Meddi, Federico Moretti and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Leukemia cutis as the first manifestation of acute myeloid leukemia.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elisa BuzzattiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Cristina MauroDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Caterina BottiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Roberta PresicciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giovangiacinto PaternoUOSD Mieloproliferative, Policlinico Tor Vergata, Rome, Italy.
Raffaele PalmieriDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Carmelo GurnariDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Flavia MallegniDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Elisa MeddiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Federico MorettiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Lucia CardilloDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Valeria MezzanotteDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Kristian TakaDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Lucrezia De MarchiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Luca MaurilloUOSD Mieloproliferative, Policlinico Tor Vergata, Rome, Italy.
Francesco BuccisanoDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Adriano VendittiDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Maria Ilaria Del PrincipeDepartment of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia Cutis (LC) in acute myeloid leukemia (AML) is typically managed within the context of systemic AML therapy, namely intensive chemotherapy (IC). In frail patients, though, viable options are hypomethylating agents (HMAs) associated with Venetoclax (VEN), but data on the efficacy of this approach in this specific setting is scarce. Here, we report our experience and provide a short review of the previous cases of LC treated with HMAs plus VEN to underline the efficacy of such treatment in LC patients who are unsuitable for IC.

Indexed as

Acute myeloid leukemiaDemethylating agentsLeukemia cutisVenetoclax

Identifiers

PMID40084096
PMCPMC11906129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.